The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Overcoming Barriers To Improved Physical Health In People With Severe Mental Illness
Funder
National Health and Medical Research Council
Funding Amount
$864,658.00
Summary
People with severe mental illness have high rates of cardiometabolic disease and reduced life-expectancy. Public intervention campaigns have had little impact on component risks (obesity, smoking, physical inactivity, poor nutrition). This study will determine factors associated with changes in cardiometabolic profiles in people with severe mental illness; examine impediments to risk modification; and develop targeted interventions for implementation within mental health services.
Roles Of Muscarinic M3 Receptors In Antipsychotic-induced Metabolic Side-effects: Prevention And Treatment Of Antipsychotic-induced Insulin Dysregulation
Funder
National Health and Medical Research Council
Funding Amount
$603,825.00
Summary
Antipsychotic drugs are used to treat various mental disorders, such as schizophrenia, bipolar disorder, dementia and major depression. However, these drugs cause serious metabolic side-effects leading to premature death and huge costs to the Australian health care system. This project aims to reveal the role of muscarinic M3 receptors in antipsychotic-induced insulin dysregulation that precedes diabetes. Understanding these mechanisms will provide new strategies for the prevention and treatment ....Antipsychotic drugs are used to treat various mental disorders, such as schizophrenia, bipolar disorder, dementia and major depression. However, these drugs cause serious metabolic side-effects leading to premature death and huge costs to the Australian health care system. This project aims to reveal the role of muscarinic M3 receptors in antipsychotic-induced insulin dysregulation that precedes diabetes. Understanding these mechanisms will provide new strategies for the prevention and treatment of these critical adverse effects.Read moreRead less
Improving Physical Health Outcomes For Young People With Psychotic Disorders
Funder
National Health and Medical Research Council
Funding Amount
$189,384.00
Summary
Enduring psychotic disorders are associated with a reduced life expectancy by 25 years, which is mainly due to cardiovascular disease. This project will produce a training package that will improve clinician’s skills and knowledge of screening and treatment for physical health risk factors in young people with psychosis. This project will result in the development of an intervention for reducing the prevalence of these cardiovascular risk factors known to contribute to this early mortality.
Cardiometabolic Health Of People With Severe And Persistent Mental Illness
Funder
National Health and Medical Research Council
Funding Amount
$187,322.00
Summary
People with schizophrenia have much higher rates of smoking, obesity and diabetes. To date, psycho-social interventions to reduce these physical health risk factors have had limited success. This research aims to conduct clinical trials among people with schizophrenia of 1. a novel diabetes medication to help people lose weight and gain better control of their sugars, and 2. newly developed vaporised nicotine products to help reduce cigarette smoking.
Inflammation And Oxidative Stress In Emerging Psychotic And Mood Disorders
Funder
National Health and Medical Research Council
Funding Amount
$432,619.00
Summary
We are conducting four large clinical trials testing anti-inflammatory treatments like ?-3 PUFAs and aspirin in young people who are at high-risk for psychosis or have depression. This proposal adds an important component to this research by investigating inflammatory and oxidative stress markers. We aim to determine if the investigated biomarkers predict the course of illness and response to treatments. The findings will facilitate early intervention and targeted treatment.
Interactions Between The Serotonin Transporter And Sympathetic Nervous Activation In Patients With Major Depressive Disorder - Understanding The Link Between The Brain And The Heart
Funder
National Health and Medical Research Council
Funding Amount
$527,109.00
Summary
There is evidence that patients with major depressive disorder (MDD) are at increased risk of developing heart disease. While the mechanisms responsible remain unknown we have previously demonstrated that cardiac sympathetic nervous activity in patients with MDD follows a bimodal distribution, with values in some patients being extraordinarily high. In this project we will determine the physiological consequences of sympathetic activation in patients with MDD.
Network Biomarkers Of Traumatic Stress Resilience And Sensitivity
Funder
National Health and Medical Research Council
Funding Amount
$647,344.00
Summary
Psychosocial stress is a major risk factor for several of the most debilitating mental illnesses including major depression, bipolar disorder, schizophrenia and post-traumatic stress disorder. By understanding the genomic basis of resilience and adverse response to traumatic stress in humans, we may predict and prevent psychopathology. This international collaborative research will use blood from soldiers exposed to extreme combat experience to identify biomarkers of stress and resilience.
Stress Vulnerability In Youth With Borderline Personality Disorder
Funder
National Health and Medical Research Council
Funding Amount
$873,689.00
Summary
Borderline personality disorder (BPD) is a severe mental disorder with adverse long-term outcomes, including suicide. BPD is characterised by vulnerability to stressful life events and catastrophic responses to stress. This study of youth early in the course of BPD examines the baseline biological characteristics of the stress response system, how these characteristics might be influenced by treatment and how this relates to treatment outcome. The findings will inform early intervention for BPD.
The Efficacy Of N-acetylcysteine As An Adjunctive Treatment In Unipolar Depression
Funder
National Health and Medical Research Council
Funding Amount
$443,832.00
Summary
This is evidence that the brain's antioxidant defences, particularly glutathione, are altered in depression. N-acetylcysteine (NAC), a glutathione precursor, increases antioxidant defences and has antidepressant properties in bipolar disorder. The aim of this study is to see if treatment with NAC will precent relapse and improve the symptoms of depression including functioning and quality of life. Participants will be randomly given either NAC or placebo, in addition to standard thereapy.
The Efficacy Of N-acetyl Cysteine As An Adjunctive Treatment For First Episode Psychosis
Funder
National Health and Medical Research Council
Funding Amount
$2,143,069.00
Summary
First episode psychosis may foreshadow devastating, chronic illness. Psychosis follows a staged, progressive pathway. There is evidence to suggest illness progression can be diminished and perhaps even averted if appropriate treatments are given at the early stages of illness. This project will test if N-acetycysteine (NAC) administered to young people who have experienced a first episode of psychosis can help prevent this early psychotic experience from developing into a chronic disorder.